Cargando…
The REDUCE metagram: a comprehensive prediction tool for determining the utility of dutasteride chemoprevention in men at risk for prostate cancer
Introduction: 5-alpha reductase inhibitors can reduce the risk of prostate cancer (PCa) but can be associated with significant side effects. A library of nomograms which predict the risk of clinical endpoints relevant to dutasteride treatment may help determine if chemoprevention is suited to the in...
Autores principales: | Nguyen, Carvell T., Isariyawongse, Brandon, Yu, Changhong, Kattan, Michael W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468831/ https://www.ncbi.nlm.nih.gov/pubmed/23087901 http://dx.doi.org/10.3389/fonc.2012.00138 |
Ejemplares similares
-
Early Dutasteride Monotherapy in Patients With Elevated Serum Prostate-Specific Antigen Levels Following Robot-Assisted Radical Prostatectomy
por: Lu, Chin-Heng, et al.
Publicado: (2019) -
Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016) -
Chemopreventive Potential of Dietary Nanonutraceuticals for Prostate Cancer: An Extensive Review
por: Chopra, Hitesh, et al.
Publicado: (2022) -
Update on the use of dutasteride in the management of benign prostatic hypertrophy
por: Miller, Joe, et al.
Publicado: (2007) -
Characteristics of prostate biopsy in patients under the dutasteride treatment
por: Obinata, Daisuke, et al.
Publicado: (2022)